S&P 500   3,791.49 (-1.51%)
DOW   30,569.97 (-1.19%)
QQQ   323.87 (-1.44%)
AAPL   143.15 (+-0.01%)
MSFT   234.70 (+1.02%)
FB   276.27 (-2.05%)
GOOGL   1,842.20 (-3.45%)
AMZN   3,277.91 (-1.45%)
TSLA   879.27 (-0.43%)
NVDA   520.63 (-3.12%)
BABA   263.29 (-0.99%)
CGC   38.93 (+9.60%)
GE   10.83 (-4.07%)
MU   76.70 (-3.53%)
AMD   90.74 (-4.19%)
NIO   58.19 (-3.52%)
T   29.47 (-0.94%)
F   10.84 (-3.13%)
ACB   11.43 (+7.12%)
BA   194.50 (-3.74%)
DIS   165.30 (-2.51%)
NFLX   537.79 (-4.30%)
GILD   65.68 (-1.53%)
S&P 500   3,791.49 (-1.51%)
DOW   30,569.97 (-1.19%)
QQQ   323.87 (-1.44%)
AAPL   143.15 (+-0.01%)
MSFT   234.70 (+1.02%)
FB   276.27 (-2.05%)
GOOGL   1,842.20 (-3.45%)
AMZN   3,277.91 (-1.45%)
TSLA   879.27 (-0.43%)
NVDA   520.63 (-3.12%)
BABA   263.29 (-0.99%)
CGC   38.93 (+9.60%)
GE   10.83 (-4.07%)
MU   76.70 (-3.53%)
AMD   90.74 (-4.19%)
NIO   58.19 (-3.52%)
T   29.47 (-0.94%)
F   10.84 (-3.13%)
ACB   11.43 (+7.12%)
BA   194.50 (-3.74%)
DIS   165.30 (-2.51%)
NFLX   537.79 (-4.30%)
GILD   65.68 (-1.53%)
S&P 500   3,791.49 (-1.51%)
DOW   30,569.97 (-1.19%)
QQQ   323.87 (-1.44%)
AAPL   143.15 (+-0.01%)
MSFT   234.70 (+1.02%)
FB   276.27 (-2.05%)
GOOGL   1,842.20 (-3.45%)
AMZN   3,277.91 (-1.45%)
TSLA   879.27 (-0.43%)
NVDA   520.63 (-3.12%)
BABA   263.29 (-0.99%)
CGC   38.93 (+9.60%)
GE   10.83 (-4.07%)
MU   76.70 (-3.53%)
AMD   90.74 (-4.19%)
NIO   58.19 (-3.52%)
T   29.47 (-0.94%)
F   10.84 (-3.13%)
ACB   11.43 (+7.12%)
BA   194.50 (-3.74%)
DIS   165.30 (-2.51%)
NFLX   537.79 (-4.30%)
GILD   65.68 (-1.53%)
S&P 500   3,791.49 (-1.51%)
DOW   30,569.97 (-1.19%)
QQQ   323.87 (-1.44%)
AAPL   143.15 (+-0.01%)
MSFT   234.70 (+1.02%)
FB   276.27 (-2.05%)
GOOGL   1,842.20 (-3.45%)
AMZN   3,277.91 (-1.45%)
TSLA   879.27 (-0.43%)
NVDA   520.63 (-3.12%)
BABA   263.29 (-0.99%)
CGC   38.93 (+9.60%)
GE   10.83 (-4.07%)
MU   76.70 (-3.53%)
AMD   90.74 (-4.19%)
NIO   58.19 (-3.52%)
T   29.47 (-0.94%)
F   10.84 (-3.13%)
ACB   11.43 (+7.12%)
BA   194.50 (-3.74%)
DIS   165.30 (-2.51%)
NFLX   537.79 (-4.30%)
GILD   65.68 (-1.53%)
Log in
NASDAQ:CBAY

CymaBay Therapeutics Stock Forecast, Price & News

$5.72
-0.06 (-1.04 %)
(As of 01/27/2021 01:45 PM ET)
Add
Compare
Today's Range
$5.49
Now: $5.72
$5.92
50-Day Range
$5.72
MA: $6.36
$7.29
52-Week Range
$1.21
Now: $5.72
$9.06
Volume45,166 shs
Average Volume965,336 shs
Market Capitalization$394.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
CymaBay Therapeutics logo

MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

265th out of 1,925 stocks

Pharmaceutical Preparations Industry

132nd out of 773 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBAY
CUSIPN/A
Phone510-293-8800
Employees36
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.71 per share

Profitability

Net Income$-102,810,000.00

Miscellaneous

Market Cap$394.03 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable
$5.72
-0.06 (-1.04 %)
(As of 01/27/2021 01:45 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBAY News and Ratings via Email

Sign-up to receive the latest news and ratings for CBAY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CymaBay Therapeutics (NASDAQ:CBAY) Frequently Asked Questions

How has CymaBay Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

CymaBay Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CBAY shares have increased by 274.0% and is now trading at $5.76.
View which stocks have been most impacted by COVID-19
.

Is CymaBay Therapeutics a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CymaBay Therapeutics stock.
View analyst ratings for CymaBay Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than CymaBay Therapeutics?

Wall Street analysts have given CymaBay Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CymaBay Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for CymaBay Therapeutics
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) released its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported ($0.17) EPS for the quarter, meeting analysts' consensus estimates of ($0.17).
View CymaBay Therapeutics' earnings history
.

What price target have analysts set for CBAY?

12 equities research analysts have issued 12-month price targets for CymaBay Therapeutics' stock. Their forecasts range from $9.00 to $20.00. On average, they anticipate CymaBay Therapeutics' share price to reach $12.77 in the next twelve months. This suggests a possible upside of 121.7% from the stock's current price.
View analysts' price targets for CymaBay Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of CymaBay Therapeutics' key competitors?

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the following people:
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 48, Pay $667.35k)
  • Dr. Charles A. McWherter, Sr. VP & Chief Scientific Officer (Age 66, Pay $514.65k)
  • Ms. Klara A. Dickinson-Eason, Chief Regulatory & Compliance Officer (Age 53, Pay $441.84k)
  • Mr. Daniel Menold, VP of Fin. (Age 51)
  • Mr. Paul T. Quinlan, Gen. Counsel (Age 58)
  • Mr. Ken Boehm, Sr. VP of HR
  • Mr. Patrick J. O'Mara, Sr. VP of Bus. Devel. (Age 60)
  • Dr. Robert L. Martin, Sr. VP of Manufacturing & Nonclinical Devel. (Age 59)
  • Ms. Becki Filice, Sr. VP of Portfolio & Product Leadership (Age 60)

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Kestra Private Wealth Services LLC (0.58%), Strs Ohio (0.07%) and International Assets Investment Management LLC (0.01%). Company insiders that own CymaBay Therapeutics stock include Carl Goldfischer and Sujal Shah.
View institutional ownership trends for CymaBay Therapeutics
.

Which institutional investors are buying CymaBay Therapeutics stock?

CBAY stock was acquired by a variety of institutional investors in the last quarter, including Kestra Private Wealth Services LLC, Strs Ohio, and International Assets Investment Management LLC.
View insider buying and selling activity for CymaBay Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $5.76.

How big of a company is CymaBay Therapeutics?

CymaBay Therapeutics has a market capitalization of $396.79 million. The biopharmaceutical company earns $-102,810,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. CymaBay Therapeutics employs 36 workers across the globe.

What is CymaBay Therapeutics' official website?

The official website for CymaBay Therapeutics is www.cymabay.com.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-293-8800 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.